The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

While there’s no cure for multiple sclerosis (MS), there are many treatments available. These treatments mainly focus on slowing down the progression of the disease and managing symptoms.

The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

JT Lew, PharmD, MBA, highlights that the primary challenges for patients with multiple sclerosis (MS) in accessing prescribed medications include dealing with the shock of the diagnosis ...

Relapsing-remitting multiple sclerosis is an unpredictable disease marked by relapses and remissions, but there are options ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...